IBDEI0SK ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13396,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13396,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,13396,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,13396,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,13397,0)
 ;;=D06.0^^53^593^42
 ;;^UTILITY(U,$J,358.3,13397,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13397,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,13397,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,13397,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,13398,0)
 ;;=D06.1^^53^593^43
 ;;^UTILITY(U,$J,358.3,13398,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13398,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,13398,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,13398,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,13399,0)
 ;;=D06.7^^53^593^41
 ;;^UTILITY(U,$J,358.3,13399,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13399,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,13399,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,13399,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,13400,0)
 ;;=D04.9^^53^593^44
 ;;^UTILITY(U,$J,358.3,13400,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13400,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,13400,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,13400,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,13401,0)
 ;;=C91.11^^53^593^47
 ;;^UTILITY(U,$J,358.3,13401,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13401,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,13401,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,13401,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,13402,0)
 ;;=C91.10^^53^593^48
 ;;^UTILITY(U,$J,358.3,13402,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13402,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,13402,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,13402,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,13403,0)
 ;;=C92.11^^53^593^49
 ;;^UTILITY(U,$J,358.3,13403,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13403,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,13403,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,13403,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,13404,0)
 ;;=C92.10^^53^593^50
 ;;^UTILITY(U,$J,358.3,13404,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13404,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,13404,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,13404,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,13405,0)
 ;;=D47.1^^53^593^51
 ;;^UTILITY(U,$J,358.3,13405,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13405,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,13405,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,13405,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,13406,0)
 ;;=C82.69^^53^593^52
 ;;^UTILITY(U,$J,358.3,13406,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13406,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,13406,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,13406,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,13407,0)
 ;;=C82.60^^53^593^53
 ;;^UTILITY(U,$J,358.3,13407,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13407,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,13407,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,13407,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,13408,0)
 ;;=D56.2^^53^593^54
 ;;^UTILITY(U,$J,358.3,13408,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13408,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,13408,1,4,0)
 ;;=4^D56.2
